Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

奥兹米普大受欢迎。那么,为何制药公司CEO离职了?

The Journal.

2025-05-22

19 分钟
PDF

单集简介 ...

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.  Further Listening: Trillion Dollar Shot  Why WeightWatchers Wants in on Drugs Like Ozempic   Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
更多

单集文稿 ...

  • In the world of big pharma, this is the sound of liquid gold.

  • An assembly line in Denmark fills glass vials with semaglutide.

  • It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon.

  • Where would you say Ozempic ranks in terms of successful drugs that you've covered?

  • One of the most successful of all time.

  • It's up there from a financial perspective, but also just from a cultural impact perspective.

  • It's one of the biggest deals.

  • That's rare.

  • Tell me about the company behind this blockbuster drug.

  • Well, the company is Novo Nordisk, which is based in Denmark,

  • and they've been around for about 100 years.

  • Most of that time, probably a lot of Americans never heard of it.

  • Over the last decade,

  • our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut.

  • Novo is one of the most valuable companies in Europe by stock market capitalization,

  • thanks to the spectacular success of Ozempic and its sister drug, Wagovi.

  • Last year...

  • Their combined sales of just those two drugs were over $26 billion.

  • Wow.

  • For Ozempic, I think it was up about 25% from the year before.